Table 3.
Proportion of drugs with reported affinity for each of the muscarinic receptor subtypes as a function of the total number of drugs that each anticholinergic burden tool includes.
| Affinity M1 | Affinity M2 | Affinity M3 | Affinity M4 | Affinity M5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticholinergic Burden Tool | Number Drugs | n | % | n | % | N | % | n | % | n | % |
| ADS | 117 | 58 | 49.6 | 57 | 48.7 | 58 | 49.6 | 52 | 44.4 | 49 | 41.9 |
| ARS | 49 | 38 | 77.6 | 38 | 77.6 | 38 | 77.6 | 36 | 73.5 | 35 | 71.4 |
| ACB | 99 | 68 | 68.7 | 67 | 67.7 | 68 | 68.7 | 63 | 63.6 | 60 | 60.6 |
| AAS | 29 | 20 | 69.0 | 19 | 65.5 | 20 | 69.0 | 19 | 65.5 | 19 | 65.5 |
| ABC | 27 | 18 | 66.7 | 18 | 66.7 | 17 | 63.0 | 17 | 63.0 | 17 | 63.0 |
| ACL | 49 | 25 | 51.0 | 23 | 46.9 | 25 | 51.0 | 22 | 44.9 | 23 | 46.9 |
| Cancelli | 17 | 10 | 58.8 | 10 | 58.8 | 10 | 58.8 | 9 | 52.9 | 9 | 52.9 |
| Chew’s list | 39 | 22 | 56.4 | 21 | 53.8 | 22 | 56.4 | 19 | 48.7 | 19 | 48.7 |
| Minzenberg (CI e PI) | 28 | 28 | 100.0 | 28 | 100.0 | 28 | 100.0 | 27 | 96.4 | 27 | 96.4 |
| CrAS | 59 | 33 | 55.9 | 32 | 54.2 | 33 | 55.9 | 30 | 50.8 | 29 | 49.2 |
| Summers’ DRN | 63 | 27 | 42.9 | 29 | 46.0 | 28 | 44.4 | 26 | 41.3 | 27 | 42.9 |
| MARANTE | 41 | 28 | 68.3 | 26 | 63.4 | 28 | 68.3 | 26 | 63.4 | 26 | 63.4 |
| AEC | 60 | 51 | 85.0 | 50 | 83.3 | 51 | 85.0 | 48 | 80.0 | 46 | 76.7 |
| German scale | 151 | 70 | 46.4 | 67 | 44.4 | 69 | 45.7 | 65 | 43.0 | 64 | 42.4 |
| KABS | 138 | 99 | 71.7 | 94 | 68.1 | 98 | 71.0 | 89 | 64.5 | 87 | 63.0 |
| AIS | 128 | 66 | 51.6 | 64 | 50.0 | 66 | 51.6 | 61 | 47.7 | 61 | 47.7 |
| Brazilian scale | 125 | 66 | 52.8 | 63 | 50.4 | 66 | 52.8 | 61 | 48.8 | 61 | 48.8 |
| Cao’s scale | 27 | 25 | 92.6 | 25 | 92.6 | 25 | 92.6 | 24 | 88.9 | 22 | 81.5 |
| DDS | 96 | 56 | 58.3 | 52 | 54.2 | 56 | 58.3 | 49 | 51.0 | 48 | 50.0 |
| DRS | 106 | 44 | 41.5 | 42 | 39.6 | 44 | 41.5 | 39 | 36.8 | 40 | 37.7 |
| ATS | 25 | 21 | 84.0 | 21 | 84.0 | 21 | 84.0 | 20 | 80.0 | 19 | 76.0 |
| Salahudeen | 192 | 96 | 50.0 | 93 | 48.4 | 95 | 49.5 | 86 | 44.8 | 83 | 43.2 |
| Durán | 100 | 70 | 70.0 | 68 | 68.0 | 69 | 69.0 | 64 | 64.0 | 62 | 62.0 |
ADS: Anticholinergic Drug Scale; ARS: Anticholinergic Risk Scale; ACB: Anticholinergic Cognitive Burden Scale; AAS: Anticholinergic Activity Scale; ABC: Anticholinergic Burden Classification; ACL: Anticholinergic Loading Scale; CI: Clinical Index; PI: Pharmacological Index; CrAS: Clinician-rated Anticholinergic Score; Summers’ DRN: Summers’ Drug Risk Number; MARANTE: Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale; AEC: Anticholinergic Effect on Cognition; KABS: Korean Anticholinergic Burden Scale; AIS: Anticholinergic Impregnation Scale; DDS: Drug Delirium Scale; DRS: Delirogenic Risk Scale; ATS: Anticholinergic Toxicity Score. M1—muscarinic receptor M1; M2—muscarinic receptor M2; M3—muscarinic receptor M3; M4—muscarinic receptor M4; and M5—muscarinic receptor M5. Extracted from [45].